GGrantIndex
Sort

51,593 grants matching hepatitis

A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease

$748,638
D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · UG3 · FY2020 · TR

Covalent Chemistry on Nanosubstrates Enables Molecular Analysis of Purified Extracellular Vesicles in Hepatocellular Carcinoma

$748,485
Hsian-Rong Tseng · University Of California Los Angeles · R01 · FY2024 · CA

Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis

$748,484
Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2009 · CA

The role of cancer stem cells in liver cancer heterogeneity and subtypes

$748,373
Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Coagulation Control To Protect Gaitko Lung and Liver Xenografts

$748,206
Richard N Pierson · University Of Pittsburgh At Pittsburgh · U19 · FY2012 · AI

Physiological and therapeutic effects of ANGPTL3 variants in mice and humans

$748,107
Marina Cuchel · University Of Pennsylvania · R01 · FY2022 · HL

Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

$748,101
Samuel Klein · Remd Biotherapeutics, Inc. · R42 · FY2017 · DK

Multi-Center Validation and Biologic Assessment of a Novel Pre-Transplant Biomarker Panel to Predict Liver Transplant Recipient Mortality

$748,049
Keri Elizabeth Lunsford · Rutgers Biomedical And Health Sciences · R01 · FY2024 · DK

Systems Biology Approach to Analysis of Vaccine Response in Healthy Individuals

$748,045
Anna Karolina Palucka · Baylor Research Institute · U19 · FY2014 · AI

The STOP Study

$747,833
Msc, Emily Westheimer · New York City Health/Mental Hygiene · U01 · FY2012 · PS

Integrated approaches to close the loop in type 1 diabetes

$747,802
Yogish C. Kudva · Mayo Clinic Rochester · R01 · FY2012 · DK

TOPMed Omics of Type 2 Diabetes and Quantitative Traits

$747,659
Alisa Knodle Manning · Massachusetts General Hospital · UM1 · FY2023 · DK

Assessing the impact of acquired immunodeficiency on congenital Zika virus

$747,439
David H Oconnor · University Of Wisconsin-Madison · R01 · FY2019 · AI

Assessing the impact of acquired immunodeficiency on congenital Zika virus

$747,439
David H Oconnor · University Of Wisconsin-Madison · R01 · FY2020 · AI

Assessing the impact of acquired immunodeficiency on congenital Zika virus

$747,439
David H Oconnor · University Of Wisconsin-Madison · R01 · FY2022 · AI

Assessing the impact of acquired immunodeficiency on congenital Zika virus

$747,439
David H Oconnor · University Of Wisconsin-Madison · R01 · FY2021 · AI

Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines

$747,395
David R. Milich · Vaccine Research Institute Of San Diego · R01 · FY2008 · AI

Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr

$747,226
Kirill Ostanin · Navigen, Inc. · R44 · FY2014 · AR

Genetic Epidemiology of Complex Traits

$747,204
Joan E. Bailey-Wilson · National Human Genome Research Institute · ZIA · FY2015 · HG

Phase I Trials of Anti-Cancer Agents

$747,189
Michael R Grever · Ohio State University · U01 · FY2009 · CA

Dynamics of antigen specific B and Tfh responses during acute and chronic HCV

$747,129
Arash Grakoui · Emory University · R01 · FY2020 · AI

Role of mitochondrial extracellular vesicles in CVB3 myocarditis by sex

$747,061
Delisa Fairweather · Mayo Clinic Jacksonville · R01 · FY2022 · HL

Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis B

$747,013
Marc Ghany · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2011 · DK

The Staying Safe Intervention: Preventing HCV among Young Opioid Injectors

$746,948
Pedro Mateu-Gelabert · National Development And Research Institutes, Inc. · R01 · FY2017 · DA

Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism

$746,941
Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2015 · AA